Next-generation dengue vaccines: novel strategies currently under development.
about
Tackling dengue fever: Current status and challengesMouse models to study dengue virus immunology and pathogenesisDengue viruses - an overviewGenomic approaches for understanding dengue: insights from the virus, vector, and hostDevelopment of a Robust Cytopathic Effect-Based High-Throughput Screening Assay To Identify Novel Inhibitors of Dengue VirusLive attenuated tetravalent dengue virus host range vaccine is immunogenic in African green monkeys following a single vaccination.The effects of vector movement and distribution in a mathematical model of dengue transmission.Detection of serotype-specific antibodies to the four dengue viruses using an immune complex binding (ICB) ELISARecombinant Dengue 2 Virus NS3 Helicase Protein Enhances Antibody and T-Cell Response of Purified Inactivated VaccineHonokiol, a Lignan Biphenol Derived from the Magnolia Tree, Inhibits Dengue Virus Type 2 Infection.Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 studySculpting humoral immunity through dengue vaccination to enhance protective immunityTrends in Dengue Cases Imported into the United States from Pan America 2001-2012Expression, purification, and evaluation of diagnostic potential and immunogenicity of a recombinant NS3 protein from all serotypes of dengue virusAn alphavirus vector-based tetravalent dengue vaccine induces a rapid and protective immune response in macaques that differs qualitatively from immunity induced by live virus infection.Human monoclonal antibodies derived from memory B cells following live attenuated dengue virus vaccination or natural infection exhibit similar characteristics.A dengue DNA vaccine formulated with Vaxfectin® is well tolerated, and elicits strong neutralizing antibody responses to all four dengue serotypes in New Zealand white rabbits.Dengue virus envelope protein domain I/II hinge determines long-lived serotype-specific dengue immunity.Consumer Willingness to Pay for Dengue Vaccine (CYD-TDV, Dengvaxia®) in Brazil; Implications for Future Pricing Considerations.DENV-2 subunit proteins fused to CR2 receptor-binding domain (P28)-induces specific and neutralizing antibodies to the Dengue virus in mice.Dengue virus photo-inactivated in presence of 1,5-iodonaphthylazide (INA) or AMT, a psoralen compound (4'-aminomethyl-trioxsalen) is highly immunogenic in mice.CYD-TDV dengue vaccine: systematic review and meta-analysis of efficacy, immunogenicity and safety.Dengue Virus Seroconversion in Travelers to Dengue-Endemic Areas.Vector competence of Aedes aegypti and Aedes albopictus (Diptera: Culicidae) for dengue virus in the Florida Keys.An Envelope-Modified Tetravalent Dengue Virus-Like-Particle Vaccine Has Implications for Flavivirus Vaccine Design.Feasibility and willingness to pay for dengue vaccine in the threat of dengue fever outbreaks in Vietnam
P2860
Q24288867-840D03A3-9CD9-4E2A-9E14-93B70CD66D53Q27010151-0D8B0F0C-76E1-4C5E-98D6-01E0B75A8BBCQ27026302-CE1903C9-02CD-44AF-AEC9-742186760F4FQ28073351-8B1E190E-7D84-4C35-9774-3D1191F1034AQ29306104-CACA9C31-08DA-4E3C-907C-AF4B2D144088Q33743890-C5ECFB1E-7367-4EFA-8BAC-25054E2F7532Q35034544-68C30AFA-1C44-4015-B4AE-5C2DF1C22B7BQ35081258-1BCA487C-3585-4FE5-8BCE-832FE0062084Q35976650-B933DE01-19EF-4513-8CC9-1248B74AE399Q36096412-0F68FFBF-3A54-4A4E-93A2-6C1594285C73Q36288109-FD08A82D-8AFB-4938-9CA4-391B1CC5B5F4Q36382589-62F9F163-8641-4323-8E2A-C1A0FEA77A45Q36444531-6C07F675-0C3C-4C42-8BCF-7D7009411668Q36457958-ED6AB940-1A50-49AA-835E-8529582A075BQ36667964-128E838F-125B-4CAC-8FF0-399DDCB2D7DDQ36846290-B62711FF-7409-48A5-93CE-72DB03EBDC5BQ36849774-4261BB2E-6B4A-41A2-86AF-7A692F5D6C35Q37571377-C43F0D74-900E-46D0-8DB3-19CC2069CC17Q37619957-E305C1FD-62CC-4631-943F-B2CFE296B067Q37694852-1E35F956-C743-466C-B166-F750BE4CCC93Q37694855-407C7575-1303-4024-A28C-54AC6F38B8A6Q39085489-3530BED1-79AD-42F4-98DD-A5181FA624F9Q40081659-138A10E7-03E3-4EC4-B481-7D67859022FDQ40277412-8F8E3132-A6EB-453E-990E-D4B5719472A0Q41928846-AECE611C-3FD7-4686-8408-7A8840752C1BQ57069443-74FFC8EE-EB1E-4367-B6F8-B40383EC65EB
P2860
Next-generation dengue vaccines: novel strategies currently under development.
description
2011 nî lūn-bûn
@nan
2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Next-generation dengue vaccines: novel strategies currently under development.
@ast
Next-generation dengue vaccines: novel strategies currently under development.
@en
type
label
Next-generation dengue vaccines: novel strategies currently under development.
@ast
Next-generation dengue vaccines: novel strategies currently under development.
@en
prefLabel
Next-generation dengue vaccines: novel strategies currently under development.
@ast
Next-generation dengue vaccines: novel strategies currently under development.
@en
P2860
P356
P1433
P1476
Next-generation dengue vaccines: novel strategies currently under development.
@en
P2860
P304
P356
10.3390/V3101800
P577
2011-09-26T00:00:00Z